14 January 2020
With the emergence of new health technology and advances in vaccines, manufacturers and key stakeholders can position themselves to generate big returns in the coming years. However, getting ahead of the competition will require having the right tools at your disposal, which is why Visiongain is proud to offer extensive vaccine market forecasts, as well as reports from other verticals like pharma, dermatology, and more.
Below, we’ve compiled some of the latest market info and emerging trends for your perusal.
Market Growth & Consolidation Factors
The global vaccine market is experiencing rapid growth in several sectors, one of which is the Chinese market, where expanding immunization programs are calling for increased vaccines. As newly industrialized or lesser developed countries begin constructing more comprehensive vaccine and immunization technologies, there are a lot of opportunities for investors and drug developers to be at the forefront.
Another lucrative area in the global vaccination market is creating vaccines for older individuals since many children have already received the most up-to-date vaccines. Disease prevention in both old and young can help create big improvements in the long-term since vaccinations are a fraction of the cost of treating actual diseases and chronic disorders.
Vaccine Shortages & Other Industry Concerns
One important thing to note in the years ahead is that, due to the success of vaccines, like those that treat polio, smallpox, and measles, there is actually a shortage of some vaccines. In a recent article on the subject, experts said it was “ironic,” stating that vaccines have done such a great job at reducing risks people often forget how necessary they are. Some of the most pressing vaccine shortages include that for varicella, the pneumococcal conjugate vaccine (PCV), which guards against pneumonia, meningitis, and ear infections, as well as tetanus vaccines.
This leaves much room for growth, in particular the increased manufacturing of important vaccines for patients around the world. Some in the industry have called for changes in legislation that would enable animal testing when human testing isn’t possible as a solution. Other have proposed solutions to the shortage like added oversight, centralization, and accountability at the governmental level.
Let Visiongain help you handle emerging trends in the vaccine market!
Visiongain can provide you with the necessary information to make informed decisions in the coming years. We offer in-depth reports in the pharmaceutical and medical industry, everything from global dermatology market breakdowns to medical device forecasts, and more.
For more than 20 years, the team from Visiongain has been helping key stakeholders in a variety of industries excel. With more than 1,500 reports across over 18 market verticals, it’s easy to find the insight you need.
Call today at +44 (0) 20 7549 9987 or visit us online for more information.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth